Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Thursday’s results are the first from several studies ... Lilly currently sells the medicine tirzepatide as weight-loss drug Zepbound and diabetes treatment Mounjaro, both of which are ...

Drugmaker Eli Lilly announced promising Phase 3 study results ... diabetes and weight loss. The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound ...

Orforglibron, a pill form of GLP-1 weight loss injections ... Mounjaro and Zepbound, the pharmaceuticals giant said Thursday. Lilly announced the results of its first of seven clinical trials ...

This is partly thanks to Zepbound ... weight loss option, and Eli Lilly might have just done it. In a phase 3 study, orforglipron, a once-daily weight management candidate, delivered excellent ...

Eli Lilly reported promising results ... their weight loss plateaus. But doctors say it’s difficult to go cold turkey. How to Choose: As patients consider drugs like Wegovy, Ozempic, Zepbound ...